

University of Wollongong

## Research Online

---

Faculty of Science, Medicine and Health -  
Papers: part A

Faculty of Science, Medicine and Health

---

1-1-2015

### Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers

Cameron Johnstone  
*Peter MacCallum Cancer Ctr.*

Nathanial Harris  
*University of Wollongong, nlh28@uowmail.edu.au*

Marie Ranson  
*University of Wollongong, mranson@uow.edu.au*

Anil K. Rustgi  
*University of Pennsylvania*

Robin L. Anderson  
*Peter Maccallum Cancer Ctr.*

Follow this and additional works at: <https://ro.uow.edu.au/smhpapers>



Part of the [Medicine and Health Sciences Commons](#), and the [Social and Behavioral Sciences Commons](#)

---

#### Recommended Citation

Johnstone, Cameron; Harris, Nathanial; Ranson, Marie; Rustgi, Anil K.; and Anderson, Robin L., "Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers" (2015). *Faculty of Science, Medicine and Health - Papers: part A*. 3276.  
<https://ro.uow.edu.au/smhpapers/3276>

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [research-pubs@uow.edu.au](mailto:research-pubs@uow.edu.au)

---

## **Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers**

### **Abstract**

Abstract of a poster presentation at the AACR 106th Annual Meeting, 18-22 April, 2015, Philadelphia, PA.

### **Disciplines**

Medicine and Health Sciences | Social and Behavioral Sciences

### **Publication Details**

Johnstone, C., Harris, N., Ranson, M., Rustgi, A. K. & Anderson, R. L. (2015). Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers. *Cancer Research*, 75 (Suppl. 15), 2251.

## **Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers**

Cameron N. Johnstone<sup>1</sup>, Nathaniel Harris<sup>2</sup>, Marie Ranson<sup>2</sup>, Anil K. Rustgi<sup>3</sup>, and

Robin L. Anderson<sup>1</sup>

<sup>1</sup>*Peter MacCallum Cancer Ctr., East Melbourne, Australia;*

<sup>2</sup>*University of Wollongong, Wollongong, Australia;*

<sup>3</sup>*University of Pennsylvania, Philadelphia, PA.*

### ***Poster Presentation***

#### **Introduction**

Triple-negative breast cancers have a propensity to metastasize and a poor outcome relative to other breast cancer subtypes. No molecularly targeted therapies exist for triple-negative disease and the standard of care for remains surgery followed by adjuvant radiotherapy and/or chemotherapy. Therefore, new therapies that target the molecular alterations present in triple-negative tumors are needed to either prevent metastatic dissemination or kill micrometastatic lesions at distant sites. The serglycin gene encodes a large secreted proteoglycan decorated with chondroitin sulfate modifications and expressed primarily by the hematopoietic system.<sup>1</sup> While serglycin was recently shown to be expressed by mammary epithelial cells<sup>2</sup>, its role in breast oncogenesis is unclear.

#### **Methods**

Serglycin expression was analyzed by RNA-based (qRT-PCR) and protein-based (immunohistochemistry) methods<sup>3</sup>. Serglycin expression was specifically knocked down in triple-negative breast cancer lines (MDA-MB-231\_HM4, SUM159) by shRNA technology using the pGIPZ lentiviral system. Genetically engineered cells were assessed in vitro using standard assays. Tumor growth and spontaneous metastasis to lung, liver and spleen was analyzed in vivo by orthotopic inoculation of cells into Nod.Scid.IL-2Rgamma-null (NSG)<sup>5</sup> immuno-deficient mice.

#### **Results**

Serglycin was found to over-expressed in a subset of triple-negative breast cancers as well as in several metastatic triple-negative/claudin-low breast cancer cell lines including MDA-MB-231, SUM159 and Hs578T. Knockdown of serglycin was engineered in highly-metastatic MDA-MB-231\_HM (231\_HM) cells and in a metastatic variant of SUM159 cells. In vivo experiments showed that knockdown of serglycin reduced the growth rate of primary 231\_HM tumours implanted in the mammary fat pads of mice. Moreover, following resection of the primary tumours, spontaneous metastasis to lung, liver and spleen was reduced in serglycin-depleted 231\_HM cells.

### Conclusions

The hematopoietic proteoglycan serglycin is over-expressed in a subset of triple-negative breast cancers and may represent a novel target for anti-cancer therapy.

### References:

1. Korpetinou A, et al., Serglycin: at the crossroad of inflammation and malignancy. *Front Oncol.* 2014 3:327
2. Korpetinou A, et al., Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. *PLoS One* 2013 8:e78157
3. Li XJ, et al., Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. *Cancer Res.* 2011 71:3162-3172
4. Chang XZ, et al., Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. *Breast Cancer Res.* 2007 9:R76
5. Shultz LD, et al., Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J Immunol.* 2005 174:6477-6489